These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20658437)

  • 1. Mechanisms of diabetic nephropathy--old buddies and newcomers part 2.
    Nawroth PP; Isermann B
    Exp Clin Endocrinol Diabetes; 2010 Nov; 118(10):667-72. PubMed ID: 20658437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of diabetic nephropathy--old buddies and newcomers part 1.
    Nawroth PP; Isermann B
    Exp Clin Endocrinol Diabetes; 2010 Oct; 118(9):571-6. PubMed ID: 20658438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapies in diabetic nephropathy: an update.
    Gupta A; Gupta P; Biyani M
    J Nephrol; 2011; 24(6):686-95. PubMed ID: 22058027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism.
    Balakumar P; Arora MK; Reddy J; Anand-Srivastava MB
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):129-38. PubMed ID: 19528810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Potential therapeutic targets for diabetic nephropathy].
    Makino Y; Haneda M
    Nihon Rinsho; 2009 Aug; 67(8):1627-35. PubMed ID: 19768953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
    Arora MK; Reddy K; Balakumar P
    Eur J Pharmacol; 2010 Jun; 636(1-3):137-44. PubMed ID: 20347778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.
    Lloberas N; Cruzado JM; Franquesa M; Herrero-Fresneda I; Torras J; Alperovich G; Rama I; Vidal A; Grinyó JM
    J Am Soc Nephrol; 2006 May; 17(5):1395-404. PubMed ID: 16597691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podocyte hypertrophy in diabetic nephropathy.
    Kim NH
    Nephrology (Carlton); 2005 Oct; 10 Suppl():S14-6. PubMed ID: 16174280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renal hemodynamic basis of diabetic nephropathy.
    O'Bryan GT; Hostetter TH
    Semin Nephrol; 1997 Mar; 17(2):93-100. PubMed ID: 9148381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of diabetic nephropathy in type 1 diabetic patients.
    Najafian B; Mauer M
    Diabetes Res Clin Pract; 2009 Jan; 83(1):1-8. PubMed ID: 19070384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discovery for diabetic nephropathy: trying the leap from mouse to man.
    Breyer MD
    Semin Nephrol; 2012 Sep; 32(5):445-51. PubMed ID: 23062985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of cardiovascular and renal function in subclinical and manifest diabetic nephropathy.
    Berglund J
    Acta Med Scand Suppl; 1988; 722():1-69. PubMed ID: 3163465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Physiopathology of diabetic nephropathy: what we learn from transplantation].
    Pirson Y
    Nephrologie; 1998; 19(3):105-9. PubMed ID: 9633051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update.
    Arora MK; Singh UK
    Vascul Pharmacol; 2013 Apr; 58(4):259-71. PubMed ID: 23313806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose reductase inhibitors and diabetic kidney disease.
    Oates PJ
    Curr Opin Investig Drugs; 2010 Apr; 11(4):402-17. PubMed ID: 20336588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Toll-like receptors in diabetic nephropathy.
    Mudaliar H; Pollock C; Panchapakesan U
    Clin Sci (Lond); 2014 May; 126(10):685-94. PubMed ID: 24490813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aspirin on experimental diabetic nephropathy.
    Moel DI; Safirstein RL; McEvoy RC; Hsueh W
    J Lab Clin Med; 1987 Sep; 110(3):300-7. PubMed ID: 3475395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for diabetic nephropathy.
    Bruno S; Cattaneo D; Perico N; Remuzzi G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):747-71. PubMed ID: 16262561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression.
    Alvarez ML; Distefano JK
    Diabetes Res Clin Pract; 2013 Jan; 99(1):1-11. PubMed ID: 23102915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.